Who Should Not Take Leucine Supplements
Leucine is the branched-chain amino acid most closely linked to muscle protein synthesis, and it is widely sold on its own or within BCAA and EAA products. For healthy adults eating a normal diet, it is generally considered safe. But there are specific groups for whom concentrated leucine is inappropriate or needs medical supervision. Our editorial team explains who they are and why.
Why leucine is popular
Leucine is one of the nine essential amino acids, meaning it must come from the diet. It is abundant in whey protein, meat, fish, eggs, dairy and soy. A typical UK diet with adequate protein already supplies several grams a day.
Its fame comes from its role as a signal. Leucine activates mTORC1, a key regulator of muscle protein synthesis. Studies by Norton, Layman and others showed that leucine is particularly potent in triggering this pathway after exercise.
Research in older adults by Katsanos and colleagues suggested that a higher proportion of leucine in an amino acid mixture improves the muscle-building response, which led to the "leucine threshold" concept, often cited as around 2–3 g per meal.
For people who already eat enough high-quality protein, extra leucine adds little. But even where it might help, there are situations in which taking it as a concentrated supplement is not advisable.
Maple syrup urine disease and other inborn errors
The clearest contraindication is maple syrup urine disease (MSUD), a rare inherited disorder in which the body cannot break down branched-chain amino acids. Leucine accumulates and is toxic to the brain, causing neurological damage if untreated.
In the UK, MSUD is part of the newborn blood spot screening programme, and affected people follow a lifelong, carefully controlled diet supervised by metabolic specialists. Leucine supplements are completely unsuitable for them.
Another rare condition, hyperinsulinism-hyperammonaemia syndrome, caused by mutations in the glutamate dehydrogenase gene, makes some children prone to "leucine-sensitive hypoglycaemia". Stanley and colleagues described in 1998 how protein-rich meals could trigger dangerously low blood sugar in these patients.
These disorders are rare but illustrate an important point: amino acids are biologically active. Anyone with a known metabolic disorder should never take amino acid supplements without specialist approval.
Kidney, liver and neurological conditions
People with chronic kidney disease are often advised to moderate protein intake to reduce the workload on the kidneys. Concentrated leucine or BCAA supplements add to that load and should only be used if a renal dietitian recommends them.
Liver disease is more nuanced. Specialist BCAA formulations are actually used in some patients with advanced cirrhosis to improve nutrition. This is a medical decision, and it does not mean that over-the-counter leucine products are suitable for people with liver disease.
In amyotrophic lateral sclerosis (ALS, a form of motor neurone disease), an Italian trial published in 1993 found no benefit from BCAA supplementation and raised concern about possible harm. People with motor neurone disease should therefore avoid BCAA supplements unless part of supervised research.
| Condition | Reason for caution | Recommendation |
|---|---|---|
| Maple syrup urine disease | Leucine cannot be metabolised; toxic build-up | Never use; specialist diet only |
| Leucine-sensitive hypoglycaemia | Leucine triggers excess insulin release | Avoid; specialist advice |
| Chronic kidney disease | Additional nitrogen load | Only if renal dietitian advises |
| Liver cirrhosis | Complex protein needs | Use only prescribed formulations |
| Motor neurone disease (ALS) | No benefit, possible harm in a trial | Avoid outside research |
| Pregnancy, breastfeeding | Lack of safety data for supplements | Rely on food protein |
If you have any of these conditions and are unsure whether a product contains leucine, check the label for BCAAs, EAAs, whey or "anabolic" amino acid blends, all of which supply it. A pharmacist can help you read the labels of multi-ingredient products and spot hidden sources.
Metabolic health, diabetes and high intakes
Large observational studies, including work by Newgard and colleagues, have found that raised blood levels of branched-chain amino acids are associated with insulin resistance and type 2 diabetes. Whether BCAAs contribute to the problem or are simply a marker of it is still debated.
This does not mean leucine causes diabetes, but people with insulin resistance, prediabetes or type 2 diabetes may wish to discuss supplements with their GP rather than adding large extra amounts on top of a high-protein diet.
Leucine can stimulate insulin secretion. In people taking insulin or sulfonylureas, very large doses might slightly increase the risk of low blood glucose. This is mainly a theoretical concern but worth knowing.
Research by Elango and colleagues in healthy young men suggested a tolerable upper intake of around 500 mg per kilogram of body weight per day; above this, blood ammonia started to rise. This is far beyond the 2–5 g per day used in typical supplementation, but it shows that more is not always better.
Practical guidance for everyone else
For healthy adults with no medical conditions, leucine is considered safe at the levels found in food and typical supplements. Most people meeting their protein needs from whole foods and protein powders do not need extra leucine.
- calculate your total daily protein first; leucine adds little if protein is adequate;
- prefer whole protein sources or complete EAA products over isolated leucine;
- avoid very high intakes unless advised by a professional;
- check labels of "stacks" to avoid doubling up on BCAAs.
Isolated leucine may be more relevant for older adults or those with small appetites who struggle to eat enough protein. Even then, it should complement, not replace, adequate total protein intake.
If you develop unusual symptoms such as confusion, fatigue or a change in urine smell after starting amino acid supplements, stop taking them and seek medical advice.
Vegetarians and vegans can meet their leucine needs from soy, lentils, beans and combinations of plant proteins. If total protein intake is adequate, isolated leucine supplements are rarely necessary even on a plant-based diet.
Conclusions of the editorial team
Leucine is safe for most healthy adults at normal supplement levels, but it is not universally appropriate.
People with maple syrup urine disease, leucine-sensitive hypoglycaemia, chronic kidney disease, advanced liver disease or motor neurone disease should avoid over-the-counter leucine supplements unless supervised by a specialist.
Those with insulin resistance or diabetes, pregnant or breastfeeding women and anyone on glucose-lowering medicines should get advice first. For everyone else, adequate total protein matters far more than isolated leucine.
You may also find useful our editorial guides on BCAAs versus EAAs, protein needs for older adults, and HMB supplement forms.
References
- Norton LE, Layman DK. Leucine regulates translation initiation of protein synthesis in skeletal muscle after exercise. J Nutr. 2006;136(2):533S–537S.
- Katsanos CS, Kobayashi H, Sheffield-Moore M, Aarsland A, Wolfe RR. A high proportion of leucine is required for optimal stimulation of the rate of muscle protein synthesis by essential amino acids in the elderly. Am J Physiol Endocrinol Metab. 2006;291(2):E381–E387.
- Elango R, Chapman K, Rafii M, Ball RO, Pencharz PB. Determination of the tolerable upper intake level of leucine in acute dietary studies in young men. Am J Clin Nutr. 2012;96(4):759–767.
- Newgard CB, An J, Bain JR, et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab. 2009;9(4):311–326.
- Stanley CA, Lieu YK, Hsu BY, et al. Hyperinsulinism and hyperammonemia in infants with regulatory mutations of the glutamate dehydrogenase gene. N Engl J Med. 1998;338(19):1352–1357.
- The Italian ALS Study Group. Branched-chain amino acids and amyotrophic lateral sclerosis: a treatment failure? Neurology. 1993;43(12):2466–2470.
